First patients receive experimental cancer drug in early safety trial
NCT ID NCT06475131
Summary
This is a first-in-human study to test the safety and determine the right dose of an experimental drug called BL-B16D1 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The trial will enroll patients who have already tried standard treatments without success. Researchers will carefully monitor how the body handles the drug and look for any early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
Conditions
Explore the condition pages connected to this study.